Table 5.
Samples | Untreated | NLC + ERT | ERT |
---|---|---|---|
H.C | X | X | X |
S.1 MoC | X | X | |
S.2 MoC | X | X | |
S.3 MoC | X | X | |
S.4 MoC | X | X |
Note: All the samples were analyzed in triplicate. S. sample; NLC nanostructure lipid carrier; ERT: Enzyme replacement therapy.
Samples | Untreated | NLC + ERT | ERT |
---|---|---|---|
H.C | X | X | X |
S.1 MoC | X | X | |
S.2 MoC | X | X | |
S.3 MoC | X | X | |
S.4 MoC | X | X |
Note: All the samples were analyzed in triplicate. S. sample; NLC nanostructure lipid carrier; ERT: Enzyme replacement therapy.